Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Commented On
Gene Polymorphism Associated With Slower Evoked Potential Latency
Interferon β and Glatiramer Acetate Are Clinically Similar, Says Cochrane Meta-Analysis
MRI Detects Early MS-Like Changes in Rare Eye Disease
Physical Activity Associated With Improved Quality of Life in People With MS
Evaluating Patient Preferences Is Key for MS Decision-Making
Epigenetics in MS: A Primer
MS Patients Positive for Oligoclonal Bands Have Greater Brain Atrophy
Portable Neuromodulation Device May Improve Walking in MS Patients
Novel Remyelination Assay Allows High-Throughput Drug Screening
A Better Interferon?
MS Patient, Ph.D.: Exercise in MS: Good or Bad?
Comorbidities, Both Physical and Mental, Are Pervasive in MS
Optical Coherence Tomography: New Evidence Lends Support for MS Diagnosis
Incomplete B-Cell Depletion Linked to Fewer MRI Lesions
Oral Contraceptive Use Linked to Less Severe Relapsing-Remitting MS
Blood Serum From Relapsing MS Patients May Damage the Blood-Brain Barrier
Genetic Marker May Underlie Sex Difference in MS Susceptibility
Nasal Vaccine May Be Effective for SPMS
Switches to Fingolimod, Natalizumab Show Similar Efficacy
Few MS Patients Fail to Receive Disease-Modifying Therapy
Make Way for Another MS Model?
Myelin and Axons Don’t Form a Perfect, Uniform Union
Antibody Testing Affects MS Therapy Management
Stopping Natalizumab May Increase Risk of MS Relapse
PPMS: Predictors of Disease Progression Still Unknown
Pages
« first
‹ previous
1
2
3
4
next ›
last »
Pages